2016
DOI: 10.1155/2016/8915047
|View full text |Cite
|
Sign up to set email alerts
|

Rituximab-Associated Inflammatory Progressive Multifocal Leukoencephalopathy

Abstract: Progressive multifocal leukoencephalopathy (PML) is a rare disease of the immunosuppression that results from neurotropic invasion of the JC virus which leads to demyelination of oligodendrocytes. Immune reconstitution inflammatory syndrome (IRIS), on the other hand, is a condition of inflammation that develops as the immune system reconstitutes. This case report describes a case of a 35-year-old HIV-negative male who presented with three weeks of right lower extremity paresthesias as well as right upper extre… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 4 publications
(8 reference statements)
0
2
0
1
Order By: Relevance
“…For patients taking rituximab, the period of immunosuppression usually lasts six months to two years [23], but there are reports that B-cells have reappeared at 110 days, and it is unclear if a stimulus such as the one from a coronavirus infection like COVID-19 could trigger a more drastic and earlier response. Additionally, cases of early IRIS after rituximab therapy have also been reported, such as the case reported by Punch et al [24].…”
Section: Discussionmentioning
confidence: 87%
“…For patients taking rituximab, the period of immunosuppression usually lasts six months to two years [23], but there are reports that B-cells have reappeared at 110 days, and it is unclear if a stimulus such as the one from a coronavirus infection like COVID-19 could trigger a more drastic and earlier response. Additionally, cases of early IRIS after rituximab therapy have also been reported, such as the case reported by Punch et al [24].…”
Section: Discussionmentioning
confidence: 87%
“…mAb acting against tumor antigen may cause fever, chills, respiratory complaints, and rashes. In rare cases, treatment with Rituximab (anti-CD20 mAb) may lead to progressive multifocal leukencephalopathy (PML) 128 . One typical side effect that may be caused by the anti-EGFR mAb Cetuximab is rashes, of which the etiology is still not completely clarified 129 .…”
Section: Chances and Risksmentioning
confidence: 99%
“…Gegen Tumorantigen-gerichtete mAb können Fieber, Schüttelfrost, Atembeschwerden und Hautausschläge verursachen. Unter der Behandlung von Rituximab (anti-CD20 mAb) kann in seltenen Fällen eine progressive multifokale Leukenzephalopathie (PML) auftreten 128 . Eine typische Nebenwirkung, die der anti-EGFR mAb Cetuximab hervorrufen kann, ist ein Hautausschlag, dessen Ätiologie immer noch nicht vollständig geklärt ist 129 .…”
Section: Chancen/ Risikenunclassified